Agios to Participate in December Investor Conference

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ: AGIO) will present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on December 7, 2022, at 11:25 a.m. ET. The presentation will be accessible via a live webcast on the company's website under the "Events & Presentations" section. A replay will be available for at least two weeks post-event. Agios focuses on therapies for rare diseases and is known for its first-in-class pyruvate kinase (PK) activator for adults with PK deficiency. The company is advancing its clinical pipeline for various hematological conditions.

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022, at 11:25 a.m. ET.

A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Investor and Media Contact:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com

FAQ

When will Agios Pharmaceuticals present at the Bank of America Virtual Biotech Conference?

Agios Pharmaceuticals is scheduled to present on December 7, 2022, at 11:25 a.m. ET.

How can I access the Agios Pharmaceuticals presentation?

The presentation can be accessed via a live webcast on Agios's website in the "Events & Presentations" section.

What is the focus of Agios Pharmaceuticals?

Agios Pharmaceuticals focuses on developing therapies for rare diseases, particularly in cellular metabolism.

What notable products does Agios Pharmaceuticals market?

Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency.

What is Agios Pharmaceuticals' stock symbol?

The stock symbol for Agios Pharmaceuticals is AGIO.